Shield Therapeutics PLC (LON:STX)

Shield Therapeutics PLC (LON:STX)


Share Price
105.50 p
Change
1.5 (1.44 %)
Market Cap
£123.63 m
Proactive Investors - Run By Investors For Investors

Shield Therapeutics PLC

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  The Company’s clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron...

EPIC: STX
Market: LSE:STX
52-week High/Low: 122.250p / 27.000p
Sector: Pharma & Biotech
Market Cap: £123.63 m
Website: www.shieldtherapeutics.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Shield Therapeutics PLC


Shield Therapeutics PLC Snapshot

Our Strategy & Values

The commercial strategy of the Group has a number of key elements:

Our Strategy

1

To launch Feraccru® into key markets using our own highly experienced field-based sales teams;

2

To build a scalable supportive infrastructure to facilitate this and future commercialisation efforts including elements such as business development and marketing;

3

To ensure best use of clinical and pharmaco-economic data to develop the commercial arguments that will facilitate reimbursement of Feraccru® at a premium price in its chosen markets, yet ensure payers recognise the significant cost advantages over IV iron in the pricing achieved;

4

To develop plans and prepare for the launch of Feraccru® into the US market, informed by the launch in Europe, either using newly established field-based teams and utilising the established infrastructure, or via out-licensing with a suitable partner;

5

To evaluate opportunities to out-licence PT20 to a commercial partner to conduct Phase 3 trials and to launch PT20 in certain non-core markets with the Group potentially retaining the rights to core markets, where the Group will be able to leverage its then existing commercial infrastructure;

6

To consider, where appropriate, out-licensing opportunities for Feraccru® in peripheral markets;

7

To consider in-licensing or acquiring other products, whether already marketed or close to market that would enhance the Group’s offering in its core markets, particularly focused on products that bolt onto the core iron deficiency offering with Feraccru® and enhance the indication specialisms;

8

To seek to change the treatment guidelines for the treatment of IDA in general and specifically in core indications such as IDA in IBD and CKD meaning Feraccru® is recognised as clear second line therapy ahead of IV iron;

9

To consider further development or out-licence opportunities for other assets.

Our Values

  • Patient centric: The patients our therapies treat are at the heart of why we do it
  • Ethical: Always professional with the highest of standards
  • Product focused: We have a great track record of identifying value and are always looking for more
  • Freedom to operate: It is “our” Company and we avoid hierarchy, we challenge to succeed
  • Relationships: Strong and human… everyone is valuable
  • Continuously develop: We only want people who are committed, effective and determined to succeed

 

Feraccru®

Feraccru® (Ferric Maltol) is a stable, non-salt, oral formulation of ferric iron, which has a novel mechanism of action compared to salt-based oral iron therapies.

For further information on Feraccru® please click here.
 

Pipeline product candidates

PT20

PT20 is a novel iron-based phosphate binder that we are developing for the treatment of hyperphosphatemia. The integration of adipic acid to form PT20 increases the phosphate binding capacity by a factor of three, compared to the unmodified iron oxide. The manufacturing process also results in particles of a very small size, which maximises the surface available for phosphate binding.
PT20 is exclusively licensed from the Medical Research Council in the United Kingdom.

PT30 and PT40

PT30 is a novel IV iron formulation and PT40 is being developed to be the first generic version of iron sucrose.

Carl Sterrit
Chief Executive Officer and Co-Founder

James Karis
Non-Executive Director

Peter Llewellyn-Davies
Non-Executive Director

Rolf Hoffman
Non-Executive Director

Hans Peter Hasler
Non-Exectuive Director

Tim Watts
Interim CFO

Dr Mark Sampson
Chief Medical Officer

Dr Jackie Mitchell
VP Regulatory Affairs and Quality
 

David Childs
Director of Product Supply and Commercial Alliances

Lucy Bailey
Senior Legal Counsel and Company Secretary

Click here to view share price summary.

London, UK

16 Upper Woburn Place
Euston
London, WC1H 0AF

t+44 (0) 207 186 8500

e[email protected]

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

e[email protected]

Wollerau, Switzerland

Sihleggstrasse 23, 
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

e[email protected]

Berlin, Germany

Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin
Germany

t+44 (0) 207 186 8500

e[email protected]

 

Advisor Contacts

Nominated Advisor and Joint Broker

Liberum, Ropemaker Place
25 Ropemaker Street, London
EC2Y 9LY

Tel: +44 (0)20 3100 2000

Joint Broker

Peel Hunt LLP
120 London Wall
London
EC2Y 5ET

Tel: +44 (0)20 7418 8900

Auditors

KPMG LLP, Quayside House, 110 Quayside
Newcastle Upon Tyne
NE1 3DX

Tel: +44 (0)19 1401 3700

Legal Advisors

Stephenson Harwood LLP
1 Finsbury Circus, London
EC2M 7SH

Tel: +44 (0)20 7329 4422

Tax Advisors

Ernst & Young LLP
Citygate 
St James’ Boulevard Newcastle upon Tyne 
NE1 4JD

Tel: +44 (0)19 1247 2500

Financial PR

Consilium Strategic Communications
41 Lothbury, London
EC2R 7HG

Tel: +44 (0)20 3709 5700

Registrar

Link Asset Services Limited
The Registry
34 Beckenham Road
Beckenham
Kent
BR3 4TU

Tel: +44 (0)871 664 0300

Analysts Coverage

Roger Franklin, Liberum Capital Limited
Amy Walker, Peel Hunt
Nick Keher, RBC Capital

Shield Therapeutics plc

Shield Therapeutics plc
Northern Design Centre
Gateshead Quays, Gateshead
NE8 3DF

Tel: +44 (0)191 511 8500

Email: [email protected]

 

London, UK

16 Upper Woburn Place
Euston
London, WC1H 0AF

t+44 (0) 207 186 8500

e[email protected]

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

e[email protected]

Wollerau, Switzerland

Sihleggstrasse 23, 
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

e[email protected]

Berlin, Germany

Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin
Germany

t+44 (0) 207 186 8500

e[email protected]

 

Columns Including STX

VIEW ALL

Market Reports Including STX

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use